– Jefferies 2016 Healthcare Conference Presentation
– Company Update Webcast June 8 in New York

SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced two upcoming events taking place on Wednesday, June 8 in New York. Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 10:30 a.m. Eastern. Later that day, Immune Design will host a Company Update Event: “Progress, Platforms and Paths Forward: Immune Design Update” at 5 p.m. Eastern.

A live webcast of both presentations will be available online from the investor relations page of the company’s corporate website at http://ir.immunedesign.com/events.cfm.  After the live webcast, an archive of the presentation will be available on the company website for 30 days.

Investors and analysts who would like to attend the Immune Design event in New York should contact Jennifer Cortes at jennifer.cortes@immunedesign.com.

Presentations at the June 8 event will include:

Targeting and Activating the Dendritic Cell in vivo

David Baltimore, Ph.D., President Emeritus, California Institute of Technology; Nobel Laureate

G100 and the Intratumoral Immune Activation Approach

Francine M. Foss, M.D., Professor of Medicine, Yale Cancer Center

CMB305: the Specific Antigen Approach to Treat Sarcoma

Robert G. Maki, M.D., Ph.D., Professor of Medicine, Pediatrics and Orthopaedics, Mt. Sinai Hospital; Director of Translational Research, Sarcoma Alliance for Research Through Collaboration

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the two-pronged focus of Immune Design’s ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

CONTACT: Media Contact
Julie Rathbun
Rathbun Communications

Investor Contact
Shari Annes
Annes Associates